Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price […]